A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)

ATHENA (ClinicalTrials.gov identifier: NCT03522246) was designed to evaluate rucaparib first-line maintenance treatment in a broad patient population, including those without or (BRCA) mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics suc...

Full description

Bibliographic Details

Published in:	Journal of clinical oncology Vol. 40; no. 34; p. 3952
Main Authors:	Monk, Bradley J, Parkinson, Christine, Lim, Myong Cheol, O'Malley, David M, Oaknin, Ana, Wilson, Michelle K, Coleman, Robert L, Lorusso, Domenica, Bessette, Paul, Ghamande, Sharad, Christopoulou, Athina, Provencher, Diane, Prendergast, Emily, Demirkiran, Fuat, Mikheeva, Olga, Yeku, Oladapo, Chudecka-Glaz, Anita, Schenker, Michael, Littell, Ramey D, Safra, Tamar, Chou, Hung-Hsueh, Morgan, Mark A, Drochýtek, Vít, Barlin, Joyce N, Van Gorp, Toon, Ueland, Fred, Lindahl, Gabriel, Anderson, Charles, Collins, Dearbhaile C, Moore, Kathleen, Marme, Frederik, Westin, Shannon N, McNeish, Iain A, Shih, Danny, Lin, Kevin K, Goble, Sandra, Hume, Stephanie, Fujiwara, Keiichi, Kristeleit, Rebecca S
Format:	Journal Article
Language:	English
Published:	United States 01.12.2022
Subjects:	Carcinoma, Ovarian Epithelial - drug therapy Carcinoma, Ovarian Epithelial - genetics Female Humans Indoles - adverse effects Maintenance Chemotherapy Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - surgery Poly(ADP-ribose) Polymerase Inhibitors - adverse effects
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!